Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 17/20 | 0.52 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596516 | 0.88 | KIF11 (0.70) | KIF11TDP2GAA | |
| SCHEMBL31492431 | 0.80 | TDP2 (0.66) | KIF11TDP2GAA | |
| SCHEMBL578303 | 0.80 | TDP2 (0.66) | KIF11TDP2GAA | |
| SCHEMBL2238253 | 0.80 | KIF11 (0.77) | KIF11TDP2PKMPKLR | |
| SCHEMBL6754956 | 0.79 | KIF11 (0.68) | KIF11 | |
| SCHEMBL7376776 | 0.78 | CES1 (0.51) | KIF11 | |
| SCHEMBL7378969 | 0.77 | KIF11 (0.44) | KIF11TDP2PKMPKLR | |
| SCHEMBL9024780 | 0.76 | KIF11 (0.67) | KIF11TDP2PKMPKLR | |
| SCHEMBL5101758 | 0.76 | AHR (0.64) | PKM | |
| SCHEMBL5807896 | 0.75 | MAOB (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | claimed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | claimed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | claimed |
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2005-07-28 | — | — | US | claimed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | claimed |
| EP-1585525-B1 | USE OF THIAZOLOBENZOHETEROCYCLES FOR TREATING MULTIPLE SCLEROSIS | AVENTIS PHARMA INC (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| EP-1694658-B1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA SA (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| US-7179909-B2 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | AVENTIS PHARMA S.A. (FR) | 2007-02-20 | — | — | US | disclosed |
| EP-1694658-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO [3,4,5-DE] [4,1]BENZOTHIAZEPINE-TYPE PRODUCT | Aventis Pharma S.A. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005066146-A1 | METHOD FOR THE PRODUCTION OF A THIAZOLO[3,4,5-DE][4,1]BENZOTHIAZEPINE-TYPE PRODUCT | AVENTIS PHARMA S.A. (FR) | 2005-07-21 | — | — | WO | disclosed |
| US-20040147504-A1 | Use of Thiazolobenzoheterocycles for treating multiple sclerosis | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-29 | — | — | US | disclosed |
| WO-2004058271-A1 | USE OF THIAZOLOBENZOHETEROCYCLES FOR TREATING MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058271-A1 | USE OF THIAZOLOBENZOHETEROCYCLES FOR TREATING MULTIPLE SCLEROSIS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1000067-B1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2002-10-23 | — | — | EP | disclosed |
| US-6369221-B1 | Thiazolobenzoheterocycles, preparation and medicines containing same | AVENTIS PHARMA S.A. (FR) | 2002-04-09 | — | — | US | disclosed |
| EP-1000067-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | Aventis Pharma S.A. (FR) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005147-A1 | THIAZOLOBENZOHETEROCYCLES, PREPARATION AND MEDICINES CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165002-A1 | Process for the manufacture of a product of the thiazolo [3,4,5-de] [4,1]benzothiazepine type | CYP2S1, CYP3A4, CYP2D6 | KIF11 2007/4885TDP2 2985/4885PKM 1701/4885 |
| US-20040147504-A1 | Use of Thiazolobenzoheterocycles for treating multiple sclerosis | PMP22, LTB4R2, MYT1 | KIF11 4013/4885TDP2 2930/4885PKM 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.